and the incidence of adverse effects of Sonazoid® is 0.5%, showing a high-level of safety [2] . Simplicity and minimal risk of allergic reactions to contrast medium are also characteristics of CE-US using Sonazoid®.
Since pancreatic cancer appears as a poorly enhanced mass on contrast CT and MRI [3] , micro blood vessels in pancreatic cancer have been pathologically evaluated by measuring the microvessel density (MVD) in excised specimens. CE-US has been shown to be able to accurately evaluate vascularization of solid pancreatic lesions [4, 5] . Although several reports have suggested the usefulness of CE-US using Levovist® (Shering, Tokyo, Japan) in pancreatic tumors in clinical practice [6, 7, 8] , it has not become common because of its complicated CE-US method and inefficient visualization. CE-US using Sonazoid®, however, allows blood flow in pancreatic cancer to be detected simply and efficiently.
Since Weidner et al. initially measured MVD using anti-factor VIII antibody for the staining of micro blood vessels in 1991 [9] , many studies on the association between the prognosis of hyper vascular tumors and MVD have been performed. Assessing tumor vascularity is clinically important because of acknowledged tumor characterization. Many studies are targeting MVD as a prognostic marker of cancer. Pancreatic cancer is an aggressive and devastating disease. In Japan, the prognosis after pancreatectomy even in stage I pancreatic cancer is poorer than that of other cancers, with a 5-year-survival rate of 52.5% (1991-2000) [10] . Therefore, a more accurate preoperative evaluation of MVD in pancreatic cancer is needed for better patient management.
In this study, we investigated the correlation between CE-US findings and pathologically measured MVD in pancreatic cancer. We also investigated the clinicopathological significance of CE-US.
MATERIALS AND METHODS

Subjects
The subjects were 16 patients who underwent CE-US before surgery and were pathologically diagnosed with pancreatic ductal adenocarcinoma after resection at the Surgery Department of Kurume University between July 2007 and March 2010. A two-year follow-up period up to March 2012 was set. No preoperative chemotherapy or radiotherapy was performed in any of the patients. There were 8 males and 8 females aged 63.9±12.8 years (mean±SD), and the tumor-occupied region was located in the pancreas head (Ph) and body (Pb) of the pancreas in 13 and 3 patients, respectively. The tumor diameter averaged 26.2±8.57 mm (mean± SD). It was classified into 2 cm or smaller (TS1) or larger than 2 cm (TS2-4) following the TS classification in the General Rules for the Study of Pancreatic Cancer [11] , and 5 and 11 cases were included in the TS1 and TS2-4 groups, respectively. The applied surgical procedure was pancreatoduodenectomy (PD) (including pylorus-preserving PD (PPPD) and subtotal stomach-preserving PD (SSPPD)) in 13 patients and distal pancreatectomy (DP) in 3. The histologic type was well-differentiated adenocarcinoma in 10, moderately differentiated adenocarcinoma in 6, and poorly differentiated adenocarcinoma in 0. Eight patients each were positive and negative for lymph node metastasis. Microscopic (R1) and macroscopic (R2) residual tumor resections were performed in 2 and 1 patient, respectively. No liver or periaortic lymph node metastasis was noted before or during surgery in any patient. Adjuvant chemotherapy was performed in 13 patients after surgery (Table 1 ). This study protocol was carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) and our institutional review board. Written informed consent was obtained from all patients before CE-US.
CE-US examination
US and CE-US were performed after 6-hour fasting. CE-US was performed after observation by B-mode US. The devices and conditions used were: imaging system, TOSHIBA Aplio 80 and XG (Toshiba Medical System Corp., Otawara, Japan); sounding probe, PUT-375BT; acquisition mode, pulse subtraction-low mode; mechanical index, 0.21-0.34; gain, 70-80; and frame rate, 15 fps. After the intravenous bolus injection of Sonazoid suspension (0.5 ml), the focus was set to the lower margin of the tumor. Observation was started in the non-contrast phase immediately after contrast medium injection, and continued through the arterial phase about 15-20 sec after injection, and the venous phase about 30-45 sec after injection.
Imaging analysis
Based on the digitally stored images, the region of interest (ROI) was placed in the enhanced area in the tumor, and the luminance (dB) was numerically presented using Image J (a public domain, Java-based image processing program developed at the National Institutes of Health). TIC was prepared, and the increase from the value before contrast imaging to the maximum value (maximum value -value before contrast imag-CONTRAST-ENHANCED ULTRASONOGRAPHY IN PANCREATIC ADENOCARCINOMA ing) was regarded as the SI (Fig. 1) . The patients were divided into those with SI lower and higher than the mean SI (hypo and hyper SI groups, respectively).
Pathologic examination
Resected specimens were observed by the same pathologist with another physician specialized in pathology. The largest cross-sectional surface of the tumor in the resected specimen was immunohistochemically stained using anti-CD34 and α-SMA antibodies [5] . Three areas rich in micro blood vessels were identified under low magnification (40x). The magnification was then increased (200x), and double stainingpositive micro blood vessels were counted in each area. The mean count was adopted as the MVD (Fig. 2) .
Statistical analysis
The correlation between SI and MVD was assessed using Pearson's correlation. In addition, to investigate the clinicopathological significance of CE-US, the tumor diameter, histological type, lymph node metastasis, and outcome (disease-free survival (DFS) after surgery) were compared between the hypo and hyper SI groups.
Data are expressed as mean±SD. Differences in the tumor size, histologic type, and lymph node metastasis between the hypo and hyper SI groups were tested using the Student's t-test. DFS was analyzed using the Kaplan-Meier method, and differences between the hypo and hyper SI groups were tested using the logrank test. P<0.05 was considered significant. All the analyses were done using JMP7.0 (SAS institute, Cary, NC, USA). 
RESULTS
There were no deaths due to surgical complications or other disease in the disease-free survival period. Six patients died of the primary disease during the followup period, and all were included in the hypo SI group. Since no patient died of the primary disease throughout the follow-up period in the hyper SI group, DFS, not overall survival (OS), was selected as an investigation item concerning the prognosis, and it was defined as the period between resection and confirmation of recurrence on follow-up CT. DFS was investigated in all patients and the group with a tumor larger than 2 (Fig. 3) .
One (20%) of 5 patients with a tumor size smaller than 2 cm and 8 (72.7%) of 11 patients with a tumor size of 2 cm or larger were included in the hypo SI group. A significant difference was noted in tumor size between the hypo and hyper SI groups (P=0.009).
Five (50%) of 10 patients with well-differentiated adenocarcinoma and 4 (66.7%) of 6 patients with moderately differentiated adenocarcinoma were included in the hypo SI group. No significant difference was noted in the histologic type between the hypo and hyper SI groups (P=0.668).
Three (37.5%) of 8 lymph node metastasis-negative patients and 6 (75%) of 8 positive patients were included in the hypo SI group. No significant difference was noted in the presence or absence of lymph node metastasis between the hypo and hyper SI groups (P=0.151) ( Table 2 ).
The median DFS was 212 days (95% CI: 66-378) in the hypo SI group consisting of 9 patients and 606 days (95% CI: 240-697) in the hyper SI group consisting of 7 patients. DFS was significantly shorter in the hypo than in hyper SI group (P=0.003).
In 11 patients with a tumor size larger than 2 cm, the median DFS was 188 days (95% CI: 66-378) in the hypo SI group and 606 days (95% CI: 240-610) in the hyper SI group. Even in the 11 patients with a tumor size larger than 2 cm, DFS was significantly shorter in the hypo (8 patients) than in the hyper (3 patients) SI group (P=0.039) (Fig. 4) .
DISCUSSION
Since Weidner et al. initially measured MVD using anti-factor VIII antibody for the staining of micro blood vessels in 1991 [9] , many studies on the association between the prognosis of hypervascular tumors, such as breast cancer [12] , colon cancer [13] , gastric cancer [14] , and bladder cancer [15] , and MVD have been performed. Sonazoid®, approved in January 2007 in Japan, is an intravenous contrast medium comprised of perflubutane (C4F4) micro bubbles as the active ingredient, which are stabilized with hydrogenated egg-yolk phosphatidylcholine sodium. The mean particle size of the micro bubbles is only 2-3 μm [16] . Intravenously administered micro bubbles easily pass through capillary blood vessels in the lung and circulate throughout blood vessels in the whole body. Micro bubbles are phagocytosed by Kupffer cells after circulation but are not transferred from blood vessels, through which pure vascular images and circulatory dynamics can be observed [17] [18] [19] . Continuous observation of circulatory dynamics on CE-US became possible employing harmonic imaging at a low acoustic pressure, destroying no micro bubbles. CE-US can be performed in an outpatient consultation room and at bedside in wards, and the procedure is very safe, with an incidence of adverse effects of Sonazoid® of only 0.5%, (although administration to patients allergic to eggs or egg products is contraindicated as a rule) [2] . Simplicity and minimal problems with allergy to contrast medium and metals, compared with CT and MRI, are also characteristics of CE-US using Sonazoid®.
The association between CE-US and MVD has been reported in many hyper vascular tumors. Nagase et al. reported that CE-US and completely patent blood vessels were correlated [4] . There have been only a few reports on the association of CE-US and MVD in hypovolemic tumors, such as pancreatic cancer. D'Onofrio et al. reported a strong correlation between the contrast effect of CE-US and CD34-positive blood vessels on pathological examination in 42 pancreatic tumor patients [20] . We prepared TIC from the continuous CE-US images of pancreatic cancer and numerically measured SI, through which we could evaluate contrast enhancement of pancreatic cancer in each patient. Since a correlation was noted between the SI and MVD, CE-US may have visualized only blood flow in pancreatic cancer. All 16 patients underwent preoperative contrast CT, but contrast enhancement was poor in the pancreatic phase in all patients and evaluation of blood flow in each patient was difficult, suggesting the usefulness of CE-US using Sonazoid® for evaluation of blood flow in pancreatic cancer.
DFS was significantly shorter in the hypo than hyper SI group in all 16 patients and in 11 patients with a tumor size exceeding 2 cm. Similarly, poor contrast enhancement of pancreatic cancer was accompanied by metastasis on CE-US in many cases [21] and poorer outcomes in cases with poorer contrast enhancement [22] have been reported. Generally, the tissue oxygen level is determined by diffusion from blood vessels, and tissue 150 μm or more distant from blood vessels is considered hypoxic. A hypoxic condition is associated with tumor invasiveness, metastasis, resistance to treatment, and survival rate reduction, serving as a predictive factor in many malignant tumors [23, 24] . In addition, significantly more patients with a tumor smaller than 2 cm were included in the hyper SI group. In a nationwide survey in Japan, the 5-year survival rate and MST of patients with 2-cm or smaller pancreatic cancer (TS1) were 31.7% and 27.4 months, respectively, showing an apparently more favorable prognosis than that of patients with pancreatic cancer larger than 2 cm (TS2-TS4) [11, 25] . It was assumed that SI was strong on CE-US in pancreatic cancer with a favorable prognosis, such as TS1, because intratumoral blood flow was retained, whereas SI was weak in highly malignant pancreatic cancer with decreased intratumoral micro-blood vessels.
On the other hand, no significant differences were noted in the histologic type or lymph node metastasis between the hypo and hyper SI groups. A correlation CONTRAST-ENHANCED ULTRASONOGRAPHY IN PANCREATIC ADENOCARCINOMA between the CE-US findings and histologic type of pancreatic cancer has been reported [22, 26] . Our study did not include poorly differentiated or undifferentiated adenocarcinoma with advanced fibrosis and severe necrosis. The absence of a significant difference between the hypo and hyper SI groups may have been due to the fact that only well-and moderately differentiated adenocarcinomas were included in this study. An association of lymphangiogenesis and the micro lymphatic vessel density with lymph node metastasis has been reported [27] [28] [29] [30] . Since Sonazoid® does not transfer from blood vessels, as described above, intratumoral micro lymphatic vessels are not contrast-enhanced and thus not visualized on CE-US. Accordingly, there was no association between CE-US and the micro lymphatic vessel density, and, subsequently, no significant difference was noted in the incidence of lymph node metastasis between the hypo and hyper SI groups.
In conclusion, the vascularity of pancreatic cancer was successfully evaluated on CE-US using Sonazoid®. Since DFS was significantly shorter in the hypo than in hyper SI group, we suggested that CE-US is a useful predictor of patient prognosis after surgery for pancreatic cancer. Since the number of patients in our study was small, further study with more patients is necessary to confirm the usefulness of CE-US.
